Selection of blockbuster announcements

1、$Great Wall Motor (02333.HK) $The net profit of returning home in 2021 increased by 26.47% to 6.782 billion yuan.

Great Wall Motor announced the performance of KuaiBao in 2021, with total operating income of 136.317 billion yuan, an increase of 31.95% over the same period last year, and net profit attributable to the company's shareholders was 6.782 billion yuan, an increase of 26.47% over the same period last year. Net profit attributable to shareholders of the company excluding non-recurring profits and losses was 4.289 billion yuan, an increase of 11.8% over the same period last year; basic earnings per share was 0.74 yuan. The announcement said that the year-on-year increase in net profit attributed to the company's shareholders during the reporting period was mainly due to an increase in vehicle sales.

2、$Smoore International Holdings Limited (06969.HK) $It is expected that the total profit and comprehensive income in 2021 will increase by about 109% 13.1% compared with the same period last year.

Smoore International Holdings Limited announced that in the year ended December 31, 2021 ("fiscal year 2021"), the total profit and comprehensive income of the group are expected to increase by about 109.0% to 131.0% compared with the fiscal year 2020. There were no (a) changes in fair value of financial instruments in fiscal year 2021, and (b) listing expenses (corresponding to the loss of fair value changes in fiscal year 2020 and listing expenses of approximately RMB 1.1306 billion). The share-based payment expenses related to the pre-IPO share option scheme in fiscal year 2021 is approximately RMB 155.6 million (the corresponding payment expense in fiscal year 2020 is approximately RMB 362.9 million).

3、$Shanghai Fosun Pharmaceutical (02196.HK) $It is impossible to predict the impact on income after obtaining the MPP COVID-19 oral drug production license.

Shanghai Fosun Pharmaceutical announced that MPP (the "Drug Patent Pool Organization") granted the company's holding subsidiary Shanghai Fosun Pharmaceutical Industry the license to use relevant patents and know-how in the region to carry out the production, commercialization and related rights of COVID-19 's oral drug Molnupiravir under development. This license is a non-exclusive license; 105 low-and middle-income countries, including India, Pakistan and C ô te d'Ivoire, excluding China. Before the commercial production of the licensed cooperative drugs, the relevant technology transfer needs to be completed and the production facilities need to be approved by SRA or certified by WHO PQ. The impact of this license on the current and future revenue and profits of the Group cannot be predicted.

4、$China Mobile Limited (00941.HK) $China Mobile Limited Group, the real controller, plans to spend 3 billion-5 billion yuan to increase its A-share holdings, which has increased its holdings by 12.32016 million shares.

China Mobile Limited (00941) announced that China Mobile Limited Group, the company's controlling shareholder and actual controller, increased its holdings of 12.32016 million RMB common shares of the company on January 21, with an increase of about 710 million yuan (excluding commissions and transaction taxes). It accounts for about 0.058% of the total number of shares issued by the company (before exercising the over-allotment option). China Mobile Limited Group plans to increase its A-share holdings by choosing an opportunity to increase its A-share holdings from January 21 to December 31, 2022, and the cumulative increase amount (including this increase) is not less than RMB 3 billion yuan and not more than RMB 5 billion yuan. The share purchase price range is not set in the increase plan. China Mobile Limited Group will implement the shareholding increase plan in time according to the fluctuation of the company's stock price and the overall trend of the capital market.

5、$Pharmaron Beijing Co., Ltd.* (03759.HK) $The net profit for 2021 is expected to increase by 35% 45%.

Pharmaron Beijing Co., Ltd.* disclosed the annual performance forecast for 2021 that during the period from January 1, 2021 to December 31, 2021, the operating income is expected to reach 7.341 billion yuan to 7.495 billion yuan, an increase of 43 percent over the same period last year. The net profit attributed to shareholders of listed companies is expected to reach 1.583 billion yuan to 1.7 billion yuan, an increase of 35 percent over the same period last year.

6、Poly Xiexin Energy (03800.HK) $It is estimated that the net profit attributable to shareholders in 2021 is 5 billion yuan, and the production capacity of 30, 000 tons of granular silicon has been built

Poly Xiexin Energy announced that the Group expects to make a net profit attributable to the owner of the company of about 5 billion yuan in 2021, compared with a net loss of about 5.7 billion yuan for the same period in 2020. In 2021, the group's granular silicon output accounted for about 18% of the group's total silicon output (excluding the silicon output of the group's associated companies). The profit advantage of granular silicon has been initially shown, in the case of a substantial increase in the price of raw material industrial silicon and silicon materials. the gross profit margin of granular silicon is about 15 percentage points higher than that of bar silicon. The Group expects the division to make a profit of about 5.4 billion yuan in 2021, compared with a loss of about 4.9 billion yuan in the same period in 2020.

• Important matters

Agile Group (03383): plans to sell about 26.66% stake in Guangzhou Lihe Real Estate Development to China Overseas Land & Investment (00688) for 1.844 billion yuan.

And Platinum Medicine-B (02142): completion of the first patient administration of a new generation of anti-CTLA-4 antibodies in the global IB/IIA phase trial in China

Green Leaf Pharmaceutical (02186): confirmed by the Stock Exchange that it can proceed with the proposed spin-off and independent listing of Boan Biology.

Goliath-B (01672): announces completion of phase III clinical trial of FASN inhibitor ASC40 combined with bevacizumab in the treatment of recurrent glioblastoma

CANSINOBIO-B (06185): plan to buy back 150 million-300 million yuan A shares

Huabao International (00336): the actual controller was put on file for investigation

Shangtang-W (00020): the over-allotment option learns that the exercise of stable price period ends

San Nuo Pharmaceutical-B (02257): the over-allotment option is partially exercised at the end of the stable price period.

United Energy Group (00467): the signing of the EPCC contract involves about US $594 million

Abe Technology (02708): affiliated to sign a purchase and sales contract with Guangxi Hongyingda Electronics involving 51.805 million yuan

Shanghai Fosun Pharmaceutical (02196):: MPP authorizes Shanghai Fosun Pharmaceutical Industry to produce and commercialize COVID-19 's oral drug Molnupiravir in 105 low-and middle-income countries

Clover organism-B (02197): SCB-2019 confirmed its protective efficacy in preventing COVID-19 of all severity in phase 3 clinical trial.

Kangfang Bio-B (09926): the results of Ib/II phase clinical study of cardinide combined with chemotherapy in the treatment of advanced gastric cancer / gastroesophageal junction adenocarcinoma are released in ASCO GI.

China Evergrande Group (03333): plans to hire more intermediary agencies to assist the company in debt risk resolution

Geely Automobile (00175): Geely Holdings and Renault sign a framework agreement to launch new models for the Korean market

Midea Real Estate (03990): conclusion of 2022 property management framework and project construction framework agreement

Cosco Marine Port (01199): Tianjin Container Terminal and Tianjin Port Finance renew 2022 Agreement Deposit Agreement

Tianlun Gas (01600): affiliated Henan Tianlun signed a strategic cooperation agreement with CLP Henan.

Tsingtao Brewery (00168): sign a number of structured deposit contracts

Zheng Meiji (00564): conclude another 500 million yuan asset management contract with Zhongtai Securities

Sinotrans (00598): stock option incentive Plan approved by SASAC

Haitong (06837): about 391 million restricted shares will be listed and circulated on February 7th.

Shanghai Fudan (01385): about 4.2609 million restricted shares will be listed and circulated on February 7th.

Sihuan Medicine (00460): joint venture with Blue Crystal microorganisms to develop PHA microspheres and bio-based regenerative medical materials

• Financial report data

Great Wall Motor (02333): the net profit of returning home in 2021 increased by 26.47% to 6.782 billion yuan

Poly Xiexin Energy (03800): it is estimated that the net profit attributable to shareholders in 2021 is 5 billion yuan, and the production capacity of 30, 000 tons of granular silicon has been built.

Xiexin New Energy (00451): the net loss in fiscal year 2021 is expected to be reduced by more than 50%.

Tianjin Development (00882): Lisheng Pharmaceutical (002393.SZ) expects its return net profit to rise by 1176.80%-1525.02% in 2021.

Citigroup Medical-B (06669): adjusted net profit is expected to grow by about 111.3% to 155.8% year-on-year in 2021.

Smoore International Holdings Limited (06969): total profit and comprehensive income are expected to increase by about 109% to 131% over the same period last year.

China Petroleum & Chemical Corp Oil Service (01033): the net profit of returning home in 2021 is expected to increase by 127.85% to 180 million yuan.

Gusheng Hall (02273): the adjusted net profit in fiscal year 2021 is expected to increase by no less than 75% compared with the same period last year.

Smoore International Holdings Limited (06969): it is expected that the adjusted net profit in 2021 is about 5.18 billion-5.7085 billion yuan, an increase of 33-46.6% over the same period last year.

Pharmaron Beijing Co., Ltd.* (03759): the net profit of returning home will be increased by 35% in advance to about 1.583 billion-1.7 billion yuan.

China Longyuan Power Group Corporation (00916): the annual net profit of homecoming is expected to increase by 25% 35% compared with the same period last year.

Guotai Junan (02611): the net profit of 2021 is 15.013 billion yuan, an increase of 34.98% over the same period last year.

China Merchants (06099): annual net profit attributable to shareholders was 11.613 billion yuan, up 22.35% from the same period last year.

Green Power Environmental Protection (01330): electricity generation will increase by 21.89% to 4.035 billion degrees in 2021 compared with the same period last year.

China Lilang (01234):: retail sales of "LILANZ" products increased by 15% to 20% year on year in 2021

China Petroleum & Chemical Corp Guande (00934): the provision for impairment of Vesta equity is expected to be no more than 20 million euros in 2021.

China Oilfield Services (02883): net profit is expected to decline 87% year on year to 91% in 2021

Sanjiang Chemical Industry of China (02198): expected profit attributable to equity holders to decline by no more than 70% year on year in 2021

MONGOL MINING (00975): 428800 tons of washed coking coal products were sold in the fourth quarter, down 55% from the same period last year.

Nanjing Panda Electronics Co., Ltd. (00553): annual return net profit is reduced by 40% to 60%.

China trend (03818): retail sales of Kappa-branded stores fell 10% and 20% in the third quarter compared with the same period last year.

China Reinsurance (01508): the original premium income of Dadi property Insurance decreased by about 9.64% to 43.15 billion yuan in 2021 compared with the same period last year.

Cosco Haineng (01138):: the provision for asset impairment will reduce the net profit by 4.96 billion yuan.

New Oriental Education & Technology Group online (01797): the medium-term net loss narrowed by 19.3% to 544 million yuan compared with the same period last year will actively adjust the business line and service scope.

Cosco Haineng (01138): expected loss of 4.93 billion to 5.13 billion yuan attributable to shareholders in 2021

China Oilfield Services (02883):: provision for impairment of assets in 2021 will reduce profit by 2.01 billion yuan

New Oriental Education & Technology Group-S (09901): expected medium-term net loss of about US $800-900 million

Profit and loss Datang Environment (01272): estimated pre-tax loss of about 280 million-380 million yuan in 2021

Shanghai Electric (02727): it is estimated that the asset impairment provision of Chongqing Shenhua will reduce the return net profit by 232 million yuan in 2021.

New Oriental Education & Technology Group online (01797): the medium-term net loss narrowed by 19.3% to 544 million yuan compared with the same period last year will actively adjust the business line and service scope.

• Change of equity

Qingdao Port (06198): Qingdao SASAC will transfer 51% equity of QDP51% to Shandong Port Group free of charge.

• Loan guarantee

China Xuyang Group (01907): will provide guarantee for Xuyang China fuel 80 million yuan loan

Volkswagen Financial Holdings (00626): HK $1.1 billion loan financing granted

China China Eastern Airlines Corp Ltd shares (00670): provide a total guarantee limit of 3 billion yuan for two wholly-owned subsidiaries and their subordinates

• Repurchase cancellation

Tianlun Gas (01600): buy back 2.13 million shares at HK $19.4413 million on January 21

China Gas (00384): HK $13.6 million buys back 950000 shares on January 21

HSBC Holdings PLC (00005): buy back about 3.3133 million shares on January 21

HSBC Holdings PLC (00005): buy back 3.6565 million shares on January 20th

• Additional placement

Tencent (00700): plans to issue 8.0048 million new shares under the share incentive scheme

Anle Engineering (01977): it is proposed to grant a total of 14 million award shares to Executive Director Chen Haiming.

Skyworth Group (00751) due to exercise of share options: 10 million shares issued on January 21

Sima Ophthalmology (03309): completion of placing 76.5 million shares and issuance of 8.79 million consideration shares

Mimaitong (02192): issue 500000 shares under the share incentive scheme

Due to the exercise of the option Kangsheng Global (09960): about 280000 additional shares were issued on January 21.

Yongsheng Medical (01612): 100000 shares issued as a result of the exercise of share options by employees

Xingfa Aluminum (00098): additional 35000 shares due to the exercise of options

Conoya-B (02162): adoption of the 2022 restricted share Unit Scheme

• Stock option

Jinyang New Energy (01121): 54 million share options granted

Zhenxiong Group (00057): 6.13 million share options granted

Minimally invasive Medical (00853): grant a total of about 4.1163 million share options

Lifeng Holdings (01125): 440000 share options granted

Wuxi Apptec (02359): grant about 160900 award shares

China Tianbao Group (01427): 19.848 million award shares under the share incentive scheme

• Asset merger and acquisition

China ship Leasing (03877): plans to buy two ships for US $70 million and then lease them to earn about US $15.275 million

• Asset sale

Zhejiang Merchants Bank (02016): Shenzhen Branch has transferred the creditor's assets involving about 1.703 billion yuan in principal and corresponding interest to China Oriental Asset Management Shenzhen Branch.

Shimao Group (00813): to sell Shanghai Shimao Real Estate Development for 1.06 billion yuan

Vanke overseas (01036): the sale of properties in the UK is expected to generate a pre-tax profit of £4 million

DongFeng Motor Group (00489): plans to sell up to 40 million Stella common shares

Tianjin Port Development (03382): plans to sell 49% stake in Yuanda Logistics for 18.2423 million yuan

Oriental Enterprise Control Group (00018): plans to sell some properties in Australia for A $38 million

• Bond bill

Shangkun Real Estate (06900): the $15 million preferred note listing is expected to take effect on or around January 24th.

Greentown China (03900): a $400 million 230% credit bond to be issued due in 2025

Shangkun Real Estate (06900): repurchase and remit funds to repay 2022 bills

CSC FINANCIAL CO.,LTD (06066): issue 6 billion yuan of bonds

Country Garden Holdings (02007): subsidiary Vision International plans to issue HK $3.9 billion convertible bonds

China Construction Bank Corporation (00939): overseas issuance of US $2 billion secondary capital bonds due in 2032

China Resources Pharmaceutical (03320): subsidiary issuance of 2 billion yuan of corporate bonds